202 related articles for article (PubMed ID: 15385226)
1. Hepatitis C-related discrimination among heroin users in Sydney: drug user or hepatitis C discrimination?
Day C; Ross J; Dolan K
Drug Alcohol Rev; 2003 Sep; 22(3):317-21. PubMed ID: 15385226
[TBL] [Abstract][Full Text] [Related]
2. Hepatitis C prevalence and risk behavior of injecting drug users in Sydney: a continuing concern.
Habib SE; Lovejoy FH; Aspin C
Southeast Asian J Trop Med Public Health; 2001 Dec; 32(4):823-34. PubMed ID: 12041560
[TBL] [Abstract][Full Text] [Related]
3. Markers and risk factors for HCV, HBV and HIV in a network of injecting drug users in Melbourne, Australia.
Miller ER; Hellard ME; Bowden S; Bharadwaj M; Aitken CK
J Infect; 2009 May; 58(5):375-82. PubMed ID: 19328555
[TBL] [Abstract][Full Text] [Related]
4. Prevalence rates and risk factors for hepatitis C among drug users not in treatment in Malaysia.
Vicknasingam B; Narayanan S; Navaratnam V
Drug Alcohol Rev; 2009 Jul; 28(4):447-54. PubMed ID: 19594801
[TBL] [Abstract][Full Text] [Related]
5. Characteristics of hepatitis C infection in injecting drug users in Zadar County, Croatia.
Medić A; Dzelalija B; Sonicki Z; Zekanović D
Coll Antropol; 2008 Sep; 32(3):697-702. PubMed ID: 18982740
[TBL] [Abstract][Full Text] [Related]
6. Management of hepatitis C among drug users attending general practice in Ireland: baseline data from the Dublin area hepatitis C in general practice initiative.
Cullen W; Stanley J; Langton D; Kelly Y; Bury G
Eur J Gen Pract; 2007; 13(1):5-12. PubMed ID: 17366287
[TBL] [Abstract][Full Text] [Related]
7. Patterns of drug use and associated harms among rural injecting drug users: comparisons with metropolitan injecting drug users.
Day C; Conroy E; Lowe J; Page J; Dolan K
Aust J Rural Health; 2006 Jun; 14(3):120-5. PubMed ID: 16706881
[TBL] [Abstract][Full Text] [Related]
8. The impact of injecting drug use status on hepatitis C-related referral and treatment.
Stoové MA; Gifford SM; Dore GJ
Drug Alcohol Depend; 2005 Jan; 77(1):81-6. PubMed ID: 15607844
[TBL] [Abstract][Full Text] [Related]
9. Impact of a reduction in heroin availability on patterns of drug use, risk behaviour and incidence of hepatitis C virus infection in injecting drug users in New South Wales, Australia.
Maher L; Li J; Jalaludin B; Wand H; Jayasuriya R; Dixon D; Kaldor JM
Drug Alcohol Depend; 2007 Jul; 89(2-3):244-50. PubMed ID: 17289299
[TBL] [Abstract][Full Text] [Related]
10. A prospective study to examine persistent HCV reinfection in injection drug users who have previously cleared the virus.
Currie SL; Ryan JC; Tracy D; Wright TL; George S; McQuaid R; Kim M; Shen H; Monto A
Drug Alcohol Depend; 2008 Jan; 93(1-2):148-54. PubMed ID: 17977668
[TBL] [Abstract][Full Text] [Related]
11. Experience of hepatitis C among current or former heroin users attending general practice.
Cullen W; Kelly Y; Stanley J; Langton D; Bury G
Ir Med J; 2005 Mar; 98(3):73-4. PubMed ID: 15869062
[TBL] [Abstract][Full Text] [Related]
12. Barriers associated with the treatment of hepatitis C virus infection among illicit drug users.
Grebely J; Genoway KA; Raffa JD; Dhadwal G; Rajan T; Showler G; Kalousek K; Duncan F; Tyndall MW; Fraser C; Conway B; Fischer B
Drug Alcohol Depend; 2008 Jan; 93(1-2):141-7. PubMed ID: 17997050
[TBL] [Abstract][Full Text] [Related]
13. Coinfection with HIV and hepatitis C virus among injection drug users in southern China.
Garten RJ; Zhang J; Lai S; Liu W; Chen J; Yu XF
Clin Infect Dis; 2005 Jul; 41 Suppl 1():S18-24. PubMed ID: 16265609
[TBL] [Abstract][Full Text] [Related]
14. Co-infection by human immuno deficiency virus, hepatitis B and hepatitis C virus in injecting drug users.
Devi KhS; Brajachand N; Singh HL; Singh YM
J Commun Dis; 2005 Mar; 37(1):73-7. PubMed ID: 16637404
[TBL] [Abstract][Full Text] [Related]
15. High prevalence of HCV in a cohort of injectors on methadone substitution treatment.
Lee KC; Lim WW; Lee SS
J Clin Virol; 2008 Apr; 41(4):297-300. PubMed ID: 18191614
[TBL] [Abstract][Full Text] [Related]
16. Hepatitis C virus prevalence and outcomes among injecting drug users on opioid replacement therapy.
Hallinan R; Byrne A; Amin J; Dore GJ
J Gastroenterol Hepatol; 2005 Jul; 20(7):1082-6. PubMed ID: 15955218
[TBL] [Abstract][Full Text] [Related]
17. Exploring associations between perceived HCV status and injecting risk behaviors among recent initiates to injecting drug use in Glasgow.
Palmateer N; Anderson N; Wadd S; Hutchinson S; Taylor A; Goldberg D
Subst Use Misuse; 2008; 43(3-4):375-88. PubMed ID: 18365938
[TBL] [Abstract][Full Text] [Related]
18. Detection of multiple hepatitis C virus genotypes in a cohort of injecting drug users.
Bowden S; McCaw R; White PA; Crofts N; Aitken CK
J Viral Hepat; 2005 May; 12(3):322-4. PubMed ID: 15850474
[TBL] [Abstract][Full Text] [Related]
19. Hepatitis C virus infection, HIV co-infection, and associated risk among injecting drug users in Togliatti, Russia.
Rhodes T; Platt L; Judd A; Mikhailova LA; Sarang A; Wallis N; Alpatova T; Hickman M; Parry JV
Int J STD AIDS; 2005 Nov; 16(11):749-54. PubMed ID: 16303071
[TBL] [Abstract][Full Text] [Related]
20. Integrating multiple programme and policy approaches to hepatitis C prevention and care for injection drug users: a comprehensive approach.
Birkhead GS; Klein SJ; Candelas AR; O'Connell DA; Rothman JR; Feldman IS; Tsui DS; Cotroneo RA; Flanigan CA
Int J Drug Policy; 2007 Oct; 18(5):417-25. PubMed ID: 17854731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
